RecruitingNot Applicable

Familial Pancreatic Cancer PROPHilation Program in Italy

Italy3,000 participantsStarted 2022-12-20

Plain-language summary

The goal of the PROPH-ITA Study is to perform genetic testing in family members of pancreatic cancer patients who may have a genetic predisposition. The subjects belong to the Italian Registry of Families At Risk of Pancreatic Cancer (IRFARPC, #NCT04095195). This investigational study will assess the genetic background of subjects with familiarity with pancreatic cancer only. Participants may accept to undergo genetic testing as part of the IRFARPC registry, through a saliva-swab-based 41-gene panel test. Up to 3,000 participants will be enrolled in this study.

Who can participate

Age range18 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Being enrolled on the IRFARPC registry * Having familiarity for pancreatic cancer (according to the IRFARPC criteria, Capurso et al. Dig Liv Dis, 2020) * Willingness to participate in saliva-swab-based genetic testing Exclusion Criteria: \- Already known genetic mutation

What they're measuring

Presence - absence of predisposing mutations

Timeframe: 5 years

Trial details

NCT IDNCT05724992

SponsorAssociazione Italiana per lo Studio del Pancreas

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2027-12-20

Contact for this trial

Erica Secchettin, PharmD

0458126254 familiarita.aisp@gmail.com

View on ClinicalTrials.gov More Candidates for Hereditary Pancreatic Cancer Testing trials